Aclaris Therapeutics (ACRS) Gross Profit (2016 - 2026)

Aclaris Therapeutics' Gross Profit history runs 11 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 68.7% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $6.4 million, a 58.22% decrease from a year earlier, with the FY2025 full-year figure at $5.7 million, down 63.99% from the prior year.
• Gross Profit rose to $1.6 million in Q1 2026 per ACRS's latest filing, from $763000.0 in the prior quarter.
• Across five years, Gross Profit topped out at $18.1 million in Q3 2022 and bottomed at $298000.0 in Q1 2022.
• The 5-year median for Gross Profit is $1.7 million (2023), against an average of $4.5 million.
• Across the five-year window, Gross Profit jumped 3131.25% in 2022 and sank 91.03% in 2025, its largest moves.
• Year by year, Gross Profit stood at $6.9 million in 2022, then soared by 144.98% to $16.8 million in 2023, then sank by 49.5% to $8.5 million in 2024, then sank by 91.03% to $763000.0 in 2025, then soared by 109.83% to $1.6 million in 2026.
• Per Business Quant, the three latest ACRS Gross Profit figures stand at $1.6 million (Q1 2026), $763000.0 (Q4 2025), and $2.8 million (Q3 2025).